“It’s an exciting time at RVL Pharmaceuticals. In 2021, we executed our strategy to focus on ocular medicine and periocular rejuvenation. We divested our legacy business, fully repaid our term loans, ...

RVL Pharmaceuticals Inc. and its affiliates (together, "RVL") announced strong first-quarter performance, with total revenue ...

RVL Pharmaceuticals plc's (NASDAQ:RVLP) several operating subsidiaries are filing for bankruptcy in a prepackaged deal with lender Athyrium Capital and other key stakeholders. The reorganization will ...

RVL Pharmaceuticals PLC (RVLP) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.15 per share a year ago. These ...

Good day, and thank you for standing by. Welcome to the RVL Pharmaceuticals Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

"RVL is demonstrating that a patient-driven, professionally powered model can unlock a new category," said Lori Deo, Chief Executive Officer. "Our Q1 performance reflects not only strong demand but ...

RVL Pharmaceuticals PLC (RVLP) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.26 per share a year ago. These ...